Indica Labs, a provider of quantitative digital pathology and image management solutions, and Ibex Medical Analytics, an expert in the area of artificial intelligence (AI) based cancer diagnostics, announced an agreement to integrate the Galen AI-based cancer diagnostics platform into the HALO AP digital pathology workflow platform.
The integration between HALO AP and the Galen platform is designed to enable a seamless experience for the end-user, said the partners.
Galen adds AI-powered cancer detection, case prioritization, grading and other productivity-enhancing insights displayed directly within the HALO AP Platform, so there is no need to use a separate viewer. Where applicable, the data will be communicated with the LIS or HIS system automatically, they added.
“While Indica Labs continues to grow our state-of-the-art AI application pipeline, we also recognize the importance of interoperability with other leaders in this growing field,” said Steven Hashagen, Indica Labs CEO. “A truly seamless integration with Ibex will allow customers to make best-of-breed AI selections without compromising usability.”
“Integrated digital pathology and AI workflows are a major driver in supporting pathologists, as they are challenged by ever-increasing workloads and complexity of cancer diagnosis,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics. “By joining forces with Indica Labs, we can jointly offer end-to-end solutions enabling pathologists to accelerate adoption of new technologies, strengthen the business case for digitization and improve the quality of cancer care.”
The HALO AP platform can be fully integrated within existing LIS or HIS solutions or can operate as a standalone case and image management system for anatomic pathology, said Indica Labs. HALO AP is used by some of the largest anatomic pathology laboratories in the world, including NeoGenomics and the National Cancer Institute (NCI).
Ibex says its Galen platform uses AI algorithms to support pathologists in improving the quality of cancer diagnosis and providing productivity-enhancing insights that help reduce turnaround times.
Installed in labs worldwide and used as part of everyday clinical practice, Galen, it said, routinely detects misdiagnosed and mis-graded cancers in digitized slides, guiding pathologists to areas of cancer in support of a prompt review.
The company further outlined how, in recent clinical studies, the Galen platform demonstrated outstanding clinical outcomes, including the highest accuracy levels reported in the field for prostate cancer, 1- to 2-day reductions in total turnaround time, and 37% productivity gain for pathologists, compared to conventional microscope viewing.